Kymera Therapeutics (KYMR) AI Stock Analysis

• Market Cap: $4.31B
• Dividend Yield: N/A
• Average Volume (3M): 725.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.22
• Revenue Growth: -50.05%
• EPS Growth: -54.47%
• Country: US
• Employees: 208
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.94
• Shares Outstanding: 71,949,030
• 10 Day Avg. Volume: 607,570
• 30 Day Avg. Volume: 725,239
• PEG Ratio: -0.74
• Price to Book (P/B): 3.61
• Price to Sales (P/S): 64.14
• P/FCF Ratio: -14.56
• Enterprise Value/Market Cap: 1.05
• Enterprise Value/Revenue: 103.34
• Enterprise Value/Gross Profit: 116.22
• Enterprise Value/Ebitda: -15.11
• 1Y Price Target: $73.22
• Price Target Upside: 20.03% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 20
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $62.00 ▲(1.64% Upside)

Kymera Therapeutics' overall stock score is primarily influenced by its financial performance challenges, including declining revenues and persistent losses. The technical analysis shows positive momentum, providing some optimism. Valuation concerns due to a negative P/E ratio and lack of dividend yield weigh on the score. The earnings call provided positive strategic updates but also highlighted areas of caution.

Positive Factors

Strong Financial Position

A substantial cash position ensures Kymera can fund its R&D and clinical trials without immediate financial pressure, supporting long-term growth.

Innovative Drug Pipeline

Kymera's focus on pioneering treatments like KT-621 positions it as a leader in targeted protein degradation, potentially transforming treatment paradigms.

Strategic Partnerships

Collaborations with major pharma companies like Gilead enhance Kymera's research capabilities and market reach, bolstering its competitive edge.

Negative Factors

Declining Revenue

A decline in revenue indicates potential challenges in monetizing its pipeline, which could impact long-term financial sustainability if not addressed.

High Operational Costs

Significant operational costs may strain resources and necessitate careful financial management to maintain long-term viability.

Negative Profit Margins

Sustained negative profit margins reflect ongoing profitability challenges, which could hinder future investment and growth opportunities.

Kymera Therapeutics Business Overview & Revenue Model

Company Description

Kymera Therapeutics is a biotechnology company focused on developing innovative therapies that harness the power of targeted protein degradation to treat a variety of diseases, including cancer and autoimmune disorders. Leveraging its proprietary technology platform, Kymera aims to create a new class of drugs that can selectively eliminate disease-causing proteins, providing a novel approach to treatment in the pharmaceutical sector.

How the Company Makes Money

Kymera Therapeutics generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which provide funding for the development of its drug candidates. The company may receive upfront payments, research funding, and milestone payments as its products progress through various stages of development. Additionally, Kymera could earn royalties on future sales of any approved therapies stemming from these collaborations. The company's revenue model is heavily reliant on the successful advancement of its therapeutic candidates in clinical trials and the establishment of strategic alliances to enhance its research capabilities and market reach.

Kymera Therapeutics Financial Statement Overview

Summary

Kymera Therapeutics faces significant financial challenges, with declining revenues and persistent losses impacting profitability. Despite a strong gross profit margin, the company struggles with negative net income and operational inefficiencies. The balance sheet shows low leverage, but negative returns on equity highlight profitability issues. Cash flow improvements are modest, with ongoing challenges in generating positive operating cash flow.

Income Statement

Kymera Therapeutics has experienced declining revenue growth, with a significant drop of 24.07% in the TTM period. The company maintains a high gross profit margin of 95.34%, indicating efficient cost management. However, the net profit margin is deeply negative at -6.16%, reflecting substantial losses. The EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The company has a low debt-to-equity ratio of 0.09, suggesting conservative leverage. However, the return on equity is negative at -31.60%, indicating that the company is not generating positive returns for shareholders. The equity ratio is relatively stable, showing a solid equity base compared to total assets.

Cash Flow

Kymera Therapeutics shows a slight improvement in free cash flow growth at 5.40% in the TTM period. The operating cash flow to net income ratio is negative, indicating cash flow challenges. However, the free cash flow to net income ratio is slightly positive, suggesting some ability to cover net losses with free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	43.73M	47.07M	78.59M	46.83M	72.83M	34.03M
Gross Profit	38.89M	47.07M	78.59M	43.85M	70.44M	-28.07M
EBITDA	-299.11M	-216.24M	-143.20M	-151.66M	-97.64M	-43.72M
Net Income	-295.12M	-223.86M	-146.96M	-151.83M	-98.00M	-43.95M
Balance Sheet
Total Assets	1.10B	978.03M	575.76M	603.13M	605.90M	487.18M
Cash, Cash Equivalents and Short-Term Investments	505.68M	488.74M	374.88M	559.49M	567.61M	458.73M
Total Debt	84.00M	87.76M	84.67M	17.34M	17.96M	17.99M
Total Liabilities	155.79M	142.42M	180.79M	112.98M	146.27M	203.29M
Stockholders Equity	946.26M	835.62M	394.97M	490.15M	459.64M	283.89M
Cash Flow
Free Cash Flow	-230.21M	-207.34M	-137.31M	-155.92M	-130.54M	79.03M
Operating Cash Flow	-227.93M	-194.50M	-102.83M	-153.09M	-128.95M	88.13M
Investing Cash Flow	-58.09M	-404.08M	139.89M	20.52M	-99.83M	-422.59M
Financing Cash Flow	288.26M	608.85M	4.19M	153.00M	250.28M	289.26M

Kymera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 61.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYMR, the sentiment is Neutral. The current price of 61 is above the 20-day moving average (MA) of 59.88, above the 50-day MA of 54.19, and above the 200-day MA of 41.42, indicating a neutral trend. The MACD of 1.47 indicates Positive momentum. The RSI at 51.15 is Neutral, neither overbought nor oversold. The STOCH value of 54.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KYMR.

Kymera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AKRO	60 Neutral	$4.36B	―	-31.14%	―	―	-11.39%
KYMR	58 Neutral	$4.31B	―	-32.09%	―	-50.05%	-54.47%
CRNX	58 Neutral	$4.00B	―	-36.94%	―	―	-9.10%
PTGX	56 Neutral	$4.85B	111.96	8.61%	―	-34.45%	-69.75%
APLS	52 Neutral	$2.52B	66.39	14.10%	―	42.11%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MLTX	41 Neutral	$678.05M	―	-54.17%	―	―	-157.74%

Kymera Therapeutics Corporate Events

Kymera Therapeutics Reports Q3 2025 Financial Results

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, pioneering the field of targeted protein degradation to address critical health problems.

Kymera Therapeutics’ Earnings Call Highlights Growth and Challenges

Kymera Therapeutics’ recent earnings call painted a picture of a company on the rise, marked by significant advancements in its STAT6 and IRF5 programs and strategic partnerships. The sentiment was largely positive, reflecting a strong financial position and a clear path forward for its pipeline. However, there were notes of caution regarding high expenses and limited data from the Phase Ib trial, along with the challenges posed by placebo effects in trials.

Kymera Therapeutics Advances KT-621 Study for Atopic Dermatitis

Kymera Therapeutics, Inc. is conducting a Phase 2b clinical study titled ‘A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study With an Open-label Period Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis.’ The study aims to assess the effectiveness and safety of KT-621, an oral drug, in reducing the severity of moderate to severe atopic dermatitis, a prevalent form of eczema.

Kymera Therapeutics Announces New Chief Legal Officer

On September 3, 2025, Kymera Therapeutics announced the retirement of Ellen Chiniara as Chief Legal Officer, with Brian R. Adams succeeding her. This leadership change is part of Kymera’s strategic efforts to advance its novel programs in the field of immunology, aiming to redefine treatment possibilities with groundbreaking oral medicines.

The most recent analyst rating on (KYMR) stock is a Hold with a $43.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Kymera Therapeutics’ Earnings Call: Optimism and Strategic Progress

Kymera Therapeutics’ recent earnings call painted a picture of optimism and strategic advancement. The company showcased significant progress in its clinical trials, highlighted by a robust pipeline and promising collaborations. Despite a strategic shift in the IRAK4 program, the overall sentiment remained positive, underscoring a strong financial position and a clear path forward.

Kymera Therapeutics Reports Q2 2025 Progress and Partnerships

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, leveraging targeted protein degradation technology to address previously inaccessible disease targets and pathways.